COMPANY PROFILE

Inveox

Explore full profile

Develops systems for the digitization, automation and networking of pathology laboratories

Garching bei München, GermanyFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2019

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Inveox

Inveox specializes in automating pathology labs to improve patient safety, increase lab efficiency, and unlock the potential of big data in cancer diagnostics. The company operates in the healthcare sector, focusing on pathology labs that handle tissue samples for cancer diagnosis. Inveox's core products include intelligent sample containers with integrated filters for automated assembly, an automation device that identifies and photographs tissue samples, and an encrypted web platform for seamless communication between clinics and labs. The business model revolves around selling these automated solutions to pathology labs, thereby generating revenue through product sales and potential service contracts. By streamlining the sample handling process, Inveox reduces the risk of misdiagnosis and enhances the speed and reliability of cancer testing, ultimately contributing to better patient outcomes and advancing cancer research.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Garching bei München, Germany
Employees: 7
Open positions: None listed
Dealroom signal: 65.9/100
Industry: Health
Sub-industry: Pharmaceutical, Medical Devices, Health Platform
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Tissue Engineering, Biopsy, Spinout
Technology: Artificial Intelligence, Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Aug 2019	$19M	$75M	Undisclosed	↗
SUPPORT PROGRAM✓Other financing	Oct 2018	$2K	—	EIT Health	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Growth	EBITDA	Margin
2026
2025
2024
2023
2022
2021
2020	—	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Inveox website traffic

Latest recorded traffic for Inveox is 10 monthly website visits, down 97.6% over the last three months. Inveox's team declined 12.5% over the past year.

Latest monthly visits10 3-month web change-97.6% 1-year team growth-12.5%

Monthly website visitsOct 2018–Sep 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
THTHERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care	Paris, France	Operational	73	$3.9M	$15M
VIVirtonomyData driven clinical trials on virtual patients based on an ever-expanding database to reflect anatomical variability, demographic diversity and pathological conditions	Munich, Germany	Operational
COColdplasmatechDevelops the first active wound dressing (plasma patch) for the healing of chronic wounds using cold, physical plasma	Greifswald, Germany	Operational
ANAntleron NVBioprocess solutions for advanced personalized therapies	Leuven, Belgium	Operational
IMiCellate MedicalDevelops products in the areas of cancer diagnosis, based on detection and analyses of circulating tumour cells (CTC), circulating tumour DNA (ctDNA) and germline DNA	Solna kommun, Sweden	Operational
ASAd ScientiamExploiting the immense potential of objective real-life data in patients to build new digital biomarkers	Paris, France	Operational
BIBioSerenityLeading global providers of remote diagnostic solutions	Paris, France	Operational
VIVitaDXDeveloping a solution for the early detection of bladder cancer	Paris, France	Operational